Blau Farmaceutica SA

As of June 30, 2026, Blau Farmaceutica SA carries a market capitalization of 2.32B, placing it among publicly traded companies globally. Its enterprise value stands at 2.27B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Blau Farmaceutica SA's next confirmed earnings release is scheduled for November 10, 2026.

As of June 30, 2026, Blau Farmaceutica SA has 230.98M shares outstanding.

As of June 30, 2026, Blau Farmaceutica SA trades at a trailing price-to-earnings ratio of 10.66. The price-to-sales ratio is 1.40, and the price-to-book ratio stands at 0.99.

As of June 30, 2026, Blau Farmaceutica SA trades at an EV/EBITDA multiple of 5.91 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.27 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 7.35 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Blau Farmaceutica SA trades at an EV/FCF ratio of 5.01, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 2.27B versus a market cap of 2.32B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Blau Farmaceutica SA maintains a current ratio of 3.23, meaning it holds 3.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 36.83, indicating elevated leverage, while an interest coverage ratio of 2.73 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Blau Farmaceutica SA posted a return on equity (ROE) of 10.17, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 8.14 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 6.24, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 11.57, useful for judging operating efficiency across full business cycles. The company generates approximately 940,067.37 in revenue per employee across its workforce of 1,900.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.58 indicates how many times Blau Farmaceutica SA sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Blau Farmaceutica SA recorded 65.45M in income tax expense. That works out to an effective tax rate of 21.80, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 300.18M, leaving 233.83M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Blau Farmaceutica SA's stock has gained approximately 25.10% over the past 52 weeks. The 50-day moving average sits at 10.43, while the 200-day moving average is 10.19.

Over the twelve months ended June 30, 2026, Blau Farmaceutica SA generated 1.79B in revenue and converted that into 233.83M in net income, yielding earnings per share of 0.94. EBITDA reached 383.52M, while operating income came in at 308.52M.

As of June 30, 2026, Blau Farmaceutica SA holds 884.87M in cash and equivalents against 853.09M in total debt, resulting in a net debt position of 774.30M. Total book value stands at 2.33B, with working capital of 1.49B providing operational flexibility.

Blau Farmaceutica SA produced 424.38M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -82.00M in capital expenditures, free cash flow totaled 342.38M - equivalent to 1.38 per share.

Over the twelve months ended June 30, 2026, Blau Farmaceutica SA posted a gross margin of 41.34, reflecting its pricing power and cost economics. The operating margin of 17.27 and net profit margin of 13.09 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Blau Farmaceutica SA paid dividends of 0.32 per share. The dividend payout ratio of 33.93 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 13.73, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -8.16, meaning Blau Farmaceutica SA raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Blau Farmaceutica SA's most recent stock split took place on January 6, 2026 with a 10:13 split ratio.

As of June 30, 2026, Blau Farmaceutica SA has an Altman Z-Score of 2.20, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.